XenTech
XenTech is a pioneering preclinical CRO dedicated to accelerating the development of new anti-cancer therapies. With expertise rooted in one of the world's most published PDX collections, XenTech offers innovative, science-driven preclinical services including the development of clinically relevant tumor models and targeted solutions in oncology research. The company emphasizes high-quality, ethical standards, and scientific excellence, focusing on underserved niches such as pediatric oncology and breast cancer, and developing predictive models like MATCH-R to address current research needs. XenTech collaborates with academic, institutional, and industry partners worldwide, providing reliable data to support therapeutic development and biomarker discovery.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Clinically annotated PDX model panels
Collections of characterized patient-derived xenograft models covering multiple tumor types and molecular subtypes for drug efficacy testing and biomarker discovery.
PDX-derived primary cell culture panels
Primary 2D cell culture collections derived from PDX tumors for in vitro screening and rapid profiling of compound activity.
Cell line and CTC-derived xenograft services (CDX)
Provision of xenograft studies using established cell lines or circulating tumor cell-derived explants to evaluate therapeutic efficacy.
PDX models reflecting acquired resistance to therapies
Specialized PDX collections established from tumors that demonstrated acquired resistance to targeted or recently approved therapies, intended to study resistance mechanisms and test next-line treatments.
Clinically annotated PDX model panels
Collections of characterized patient-derived xenograft models covering multiple tumor types and molecular subtypes for drug efficacy testing and biomarker discovery.
PDX-derived primary cell culture panels
Primary 2D cell culture collections derived from PDX tumors for in vitro screening and rapid profiling of compound activity.
Cell line and CTC-derived xenograft services (CDX)
Provision of xenograft studies using established cell lines or circulating tumor cell-derived explants to evaluate therapeutic efficacy.
PDX models reflecting acquired resistance to therapies
Specialized PDX collections established from tumors that demonstrated acquired resistance to targeted or recently approved therapies, intended to study resistance mechanisms and test next-line treatments.
Services
Design and conduct of in vivo efficacy and pharmacology studies using xenograft models to evaluate anticancer compounds and combinations.
Rapid in vitro compound screening using primary cell cultures derived from PDX tumors to prioritize candidates prior to in vivo testing.
Selection of appropriate tumor models, generation of molecular characterization data and exploratory biomarker studies to support translational objectives.
Design and conduct of in vivo efficacy and pharmacology studies using xenograft models to evaluate anticancer compounds and combinations.
Rapid in vitro compound screening using primary cell cultures derived from PDX tumors to prioritize candidates prior to in vivo testing.
Selection of appropriate tumor models, generation of molecular characterization data and exploratory biomarker studies to support translational objectives.
Expertise Areas
- Preclinical oncology contract research
- Patient-derived xenograft (PDX) modeling
- Cell- and CTC-derived xenograft (CDX) modeling
- Immuno-oncology preclinical models
Key Technologies
- Patient-derived xenograft (PDX) models
- Cell line / CDX xenograft models
- Primary tumor-derived 2D cell cultures
- Bioluminescence in vivo imaging
News & Updates
Presentation of new products and services, including flagship PDX panels and Match-R lines.
Engagement with the scientific community at the Biofit conference.
Update from COO on operational status during the pandemic.
Company's approach to managing the COVID-19 situation, following WHO and French guidelines.
Participation in upcoming scientific summit.
Upcoming poster presentations and research on anti-cancer therapeutics.
Presentation of new products and services, including flagship PDX panels and Match-R lines.
Engagement with the scientific community at the Biofit conference.
Update from COO on operational status during the pandemic.
Company's approach to managing the COVID-19 situation, following WHO and French guidelines.
Participation in upcoming scientific summit.
Upcoming poster presentations and research on anti-cancer therapeutics.